Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.08
-C$0.01(-13.33%)
At close: 4:00 PM EDT
C$0.08
-C$0.01(-13.33%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume35.78K
Average Volume (3M)0.00
Market Cap
C$11.52M
Enterprise ValueC$26.82
Total Cash (Recent Filing)C$17.52K
Total Debt (Recent Filing)C$19.14M
Price to Earnings (P/E)―
Beta-3.36
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,283,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginA positive TTM gross margin (~29%) with material improvement versus 2023 suggests underlying product or cost improvements. Sustained positive gross margins provide operating leverage potential and are a prerequisite for longer-term profitability if SG&A and scale dynamics are managed.
Colombian Low-cost Production FootprintOperations based in Colombia offer structural cost advantages for biomass cultivation and extract production versus higher-cost jurisdictions. Serving pharmaceutical and regulated downstream markets can support stable, higher-margin B2B contracts and export opportunities over the medium term.
Growing Asset BaseAn expanding asset base (TTM assets up to ~$12.6M) supports capacity to scale production and product development. Asset growth indicates reinvestment or acquisitions that can underpin future revenue recovery if paired with improved operational execution.
Bears Say
Negative Equity And High LeveragePersistent negative equity and sizable debt create elevated refinancing and solvency risk. With equity deficits, the company has limited cushion to absorb shocks, restricting strategic flexibility and increasing the likelihood of costly external financing or dilution over the coming months.
Ongoing Cash BurnSustained negative operating and free cash flow (~-$4.6M TTM) erodes liquidity and forces reliance on financing or asset sales. Continued cash burn undermines capacity to invest in commercialization or R&D, making the operating plan vulnerable if capital markets tighten.
Sharply Contracted Revenue And Small ScaleVery small, sharply declining revenue indicates weak market traction or execution shortcomings. Limited sales scale reduces ability to absorb fixed costs and erodes margin improvement prospects, making sustained profitability and growth harder to achieve without a clear revenue recovery.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$11.52M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is tomorrow.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―